Phase 4 N=53 Stereotaxis Study To Obliterate Persistent Ventricular Tachycardia
Ventricular Tachycardia
Primary: Percentage of Participants Free From VT at 1 Year Post-Treatment — 62 percentage of participants free from VT
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=97 Outpatient Reduction of Nocturnal Hypoglycemia by Using Predictive Algorithms and Pump Suspension in Children
Type 1 Diabetes
Primary: Comparison of the Time Spent in Hypoglycemia (<70 mg/dl, 3.9 mmol/L) Overnight on Intervention Nights Versus Control Nights, Normalized to an 8-hour Period. — 4.6; 10.1…
N/A N=31 Virtual Reality Based Testing of Power Wheelchair Driving Skills
Spinal Cord Injury · Spina Bifida · Spinal Cord Disease
Primary: Composite Power Mobility Road Test (PMRT) Scores — 95.3; 96.09; 93.75; 96.88 units on a scale
Phase 1 N=16 Bioavailability of a Fixed Dose Combination Tablet With Empagliflozin (BI 10773) and Metformin Compared With the Monocomponents and Effect of Food on Bioavailability
Diabetes Mellitus, Type 2
Primary: Empa: Area Under the Curve 0 to Infinity (AUC0-∞) — 2920; 2860; 2710 nmol*h/L
N/A N=20 Evaluation of Pancreatic Pseudocyst Drainage With a Metal Stent
Pancreatic Pseudocysts
Primary: Technical Success of Endoscopic Ultrasound-guided Single-access Pseudocyst Drainage With a Fully Covered Self-expanding Metal Stent ; Anchored With a Double Pigtail…
Phase 1 N=28 Single-dose Pharmacokinetics and Relative Bioavailability of Two Different Formulations of Opicapone
Parkinson Disease
Primary: Cmax - Maximum Observed Plasma Concentration — 327.8; 750.1 ng/mL
Phase 2 N=188 A Randomized Trial Of PF-00299804 Taken Orally Versus Erlotinib Taken Orally For Treatment Of Advanced Non-Small Cell Lung Cancer That Has Progressed After One Or Two Prior Chemotherapy Regimen
Non-small Cell Lung Cancer
Primary: Progression-Free Survival (PFS) — 8.3; 12.4 weeks — p=0.012
Phase 3 N=20 Efficacy of Intranasal Fentanyl at Reducing Pain During Abscess Incision and Drainage (I&D) in Children
Abscess · Pain
Primary: Score on the Observational Scale of Behavioral Distress Revised (OSBD-R) — 5.48; 18.92 units on a scale
Phase 3 N=1,700 Field Administration of Stroke Therapy - Magnesium (FAST-MAG) Trial
Cerebrovascular Accident
Primary: Modified Rankin Scale — 2; 2 units on a scale — p=0.28
Phase 2 N=283 The Farnesoid X Receptor (FXR) Ligand Obeticholic Acid in NASH Treatment Trial(FLINT)
Nonalcoholic Fatty Liver Disease (NAFLD) · Nonalcoholic Steatohepatitis (NASH)
Primary: Hepatic Histological Improvement in Nonalcoholic Fatty Liver Disease (NAFLD) Activity Score (NAS) — 50; 23 participants — p=0.0002
Phase 2 N=456 Generalized Anxiety Disorder Proof of Concept Efficacy and Safety Study of SEP-225441 (Eszopiclone) In GAD Subjects
Generalized Anxiety Disorder
Primary: Change From Baseline to Week 8 in the Total Score on the Hamilton Anxiety Scale (HAM-A), as Assessed by the Site-trained Rater — -10.0; -9.3; -9.5 Units on a scale
N/A N=17 Zinc and Copper Absorption in Neonates With Bilious Losses
Ileostomy
Primary: Zinc Absorption — 10.9 fractional zinc absorption (%)
N/A N=41 Partial Breast Irradiation Using Non Invasive Approach for Early Stage Breast Cancer
Breast Cancer
Primary: Early and Intermediate Toxicity — 40; 28 participants
Phase 3 N=164 Safety Evaluation of a Human Papillomavirus (HPV) Vaccine in Healthy Female Control Subjects From the GSK HPV 023 Study
Infections, Papillomavirus
Primary: Number of Subjects With Serious Adverse Events (SAEs) — 1; 1; 0 Subjects
N/A N=80 Mobile Continuing Care Approach for Youth
Addiction
Primary: Primary Substance Use (Defined as Substance Received Treatment for) — 47.5; 41.5; 14.7; 62.9 percentage of positive urines — p=<0.05